EpiBone

EpiBone is a biotechnology company dedicated to developing personalized bone and cartilage grafts based on stem cell technology and 3D imaging technology. EpiBone's craniofacial or EB-CMF product is currently being tested in its first trial to treat continuity defects of the mandible (jaw). In May 2019, the company received Investigational New Drug (IND) approval to conduct Phase I/II clinical trials for this product. EpiBone is also exploring the use of the same technology to replace cartilage and treat osteochondral injuries, as well as other applications.